ZOE GER Week ended 07 Aug 2026

Weekly Investor Report

Zoetis Inc. · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 64.82 EUR
-2.4% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -25.0% below the Trend Line and sits at 4.5% of its 52-week range. The latest completed week returned -2.4%, after a -2.5% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 48/100.

Setup score 33 out of 100
Latest Close 64.82 EUR 7 Aug 2026
1W Return -2.4% latest completed week
4W Return -2.5% short-term follow-through
12W Return 1.1% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 2.7x vs 13-week average
What is working
  • Volume is elevated versus the 13-week average, confirming attention.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -2.4% Latest completed week; four-week move -2.5%. Indicator stack 0/49 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 48/100 22 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -25.0% below the Trend Line and sits at 4.5% of its 52-week range. The latest completed week returned -2.4%, after a -2.5% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 2.7x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0612-week average 0.03

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.06Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -2.5% over four weeks, 1.1% over 12 weeks, and -47.8% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-2.4%
4W-2.5%
12W1.1%
26W-39.7%
52W-47.8%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.35Latest activity-pressure read.
Pressure change62.5%Four-week change in activity pressure.
Leadership-39.54Latest relative-leadership reading.
RS change-4.1%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 91% Model confidence 85%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength67/100Blend of value, momentum, and quality. Underlying universe rank 34; rank 1 is best.
Value65/100Relative valuation strength. Underlying universe rank 36; rank 1 is best.
Quality90/100Profitability and accounting quality. Underlying universe rank 11; rank 1 is best.
Momentum4/100Medium-term price momentum. Underlying universe rank 97; rank 1 is best.
Growth61/100Revenue and earnings growth. Underlying universe rank 40; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework86/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
10.1x
Price divided by trailing earnings.
Price / sales
2.8x
Market value relative to trailing revenue.
EV / EBITDA
8.4x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
6.6%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
71.6%
Gross profit retained from each unit of revenue.
Operating margin
37.6%
Operating profit retained from revenue.
Free-cash-flow margin
23.5%
Free cash flow generated from revenue.
Return on invested capital
25.5%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
2.3%
Latest one-year revenue growth.
EPS growth
13.5%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-0.7%
Latest one-year free-cash-flow growth.
Piotroski F-score
6/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
2.8%
Cash dividends relative to market value.
Buyback yield
12.7%
Net share repurchases relative to market value.
Shareholder yield
15.5%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.8x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment48/100

Weighted news tone is neutral across 22 relevant articles.

1 positive · 17 neutral · 4 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-52.1%Distance below the 52-week high.
13-week volatility3.7%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher9 of 2617 weeks finished lower.
Best week+8.0%Week of 22 May.
Worst week-28.5%Week of 8 May.
Latest week-2.4%Week of 7 Aug.

Shape of recent returns

Strong gains1
Modest gains8
Flat weeks0
Modest losses13
Sharp losses4
Recent vol3.7%13-week weekly-return volatility.
Base vol5.5%52-week weekly-return volatility.
Up/down split20/32Count of positive and negative weeks in the 52-week window.
Average skew2.8% / -3.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape28/100

Trend, activity pressure, participation, and risk combine to a 28/100 tape read.

 Indicator analysis9/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.06; No reversal markers Factors58/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 2; Small Cap Core rank 44 SVQF86/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 52.0 of 375 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment48/100

Weighted news tone is neutral across 22 relevant articles.

Kentucky Retirement Systems Has $4.88 Million Stock Holdings in Zoetis Inc. $ZTS Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 202664.82 EUR-2.4%86.39 EUR136.2 EUR-0.35-39.5431.1KOff
31 Jul 202666.40 EUR0.4%87.82 EUR136.9 EUR-0.60-37.195.4KOff
24 Jul 202666.14 EUR-0.8%89.15 EUR137.5 EUR-0.76-36.926.7KOff
17 Jul 202666.69 EUR0.3%90.38 EUR138.1 EUR-0.87-36.485.7KOff
10 Jul 202666.49 EUR1.0%91.65 EUR138.7 EUR-0.93-37.9611.5KOff
3 Jul 202665.82 EUR-1.0%92.79 EUR139.2 EUR-1.06-41.06852Off
26 Jun 202666.49 EUR-3.3%94.00 EUR139.7 EUR-1.15-38.611.6KOff
19 Jun 202668.77 EUR-0.3%95.45 EUR140.3 EUR-1.16-38.059.7KOff
12 Jun 202668.99 EUR-0.4%96.57 EUR140.8 EUR-1.13-37.78892Off
5 Jun 202669.28 EUR3.6%97.71 EUR141.3 EUR-1.04-38.661.3KOff
29 May 202666.86 EUR-3.5%98.80 EUR141.8 EUR-0.90-42.4112.8KOff
22 May 202669.30 EUR8.0%100.7 EUR142.3 EUR-0.72-40.6331.2KOff
15 May 202664.14 EUR-8.2%102.5 EUR142.8 EUR-0.54-43.6228.6KOff
8 May 202669.88 EUR-28.5%104.4 EUR143.5 EUR-0.23-40.3625.5KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context